BioSpace News Archive

Panbela Therapeutics, Inc. announced it has opened enrollment in the UK and Germany for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer.

Dyadic International, Inc. today provided an update regarding its Phase 1 Clinical Trial for its DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate.

DarioHealth Corp., a leader in the global digital health market, announced a new agreement with a large regional health plan to deliver highly personalized digital health solutions to more than 160,000 Plan members living with hypertension.

Infinity Pharmaceuticals, Inc. announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc. (“MEI”).

Molecure S.A. (“Molecure”: WSE: MOC) announces that it has received clearance from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) Application to conduct Phase II clinical testing of OATD-01, the first-ever chitotriosidase 1 (CHIT1) inhibitor with disease-modifying potential.

Apellis Pharmaceuticals, Inc. today announced that the company will host a conference call and webcast to discuss its second quarter 2023 financial results on Monday, July 31, 2023, at 8:30 a.m. ET.

Clarity Pharmaceuticals is pleased to announce the Phase II US-based diagnostic 64 Cu SAR-Bombesin trial (SABRE NCT05407311) 1 for patients with prostate cancer has reached its fifty percent recruitment milestone, with 25 out of 50 participants enrolled and imaged.

Heron Therapeutics, Inc. today announced a cost reduction plan and a corporate restructuring, following a strategic review of the business conducted by the new management team.

The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced the launch of two new immunoassay interference blockers, K-Block™, and Mouse-Free IgG.

A recent peer-reviewed study published in the American Journal of Clinical Oncology demonstrates tumor bed delineation superiority of Videra Surgical’s VeraForm® marker versus surgical clips for targeting breast cancer radiotherapy treatment following breast-conserving surgery.